Key facts
- This page summarizes James M. Mock's Form 4 filing for Moderna, Inc. (MRNA).
- 11 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 03 Mar 2026, 16:04.
James M. Mock - 27 Feb 2026 Form 4 Insider Report for Moderna, Inc. (MRNA)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- MRNA
- Reported as of
- 27 Feb 2026
- Net transaction value
- -$275,252
- SEC form
- 4
- Accepted by SEC
- 03 Mar 2026, 16:04:51 UTC
- Prior SEC filing
- 13 Feb 2026
- Next SEC filing
- 06 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ James Dillon, As Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
James M. Mock filed Form 4 for Moderna, Inc. (MRNA) on 03 Mar 2026.
Change
- Previous filing in this sequence was filed on 13 Feb 2026.
- Current net transaction value: -$275,252.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001736359
Primary reporting owner
Mock James M
- Relationship
- Chief Financial Officer
- Address
- C/O MODERNA, INC., 325 BINNEY STREET, CAMBRIDGE
- Signature
- /s/ James Dillon, As Attorney-in-Fact
- Signature date
- 03 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MRNA
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +329
- Change %
- +0.73%
- Price
- Shares after
- 45,553
- Date
- 27 Feb 2026
- Ownership
- Direct
- Footnotes
- F1
MRNA
transaction
Common Stock
Tax liability
- Transaction value
- $8,274
- Shares
- -160
- Change %
- -0.35%
- Price
- $51.71
- Shares after
- 45,393
- Date
- 27 Feb 2026
- Ownership
- Direct
- Footnotes
- F2
MRNA
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +774
- Change %
- +1.7%
- Price
- Shares after
- 46,167
- Date
- 27 Feb 2026
- Ownership
- Direct
- Footnotes
- F1
MRNA
transaction
Common Stock
Tax liability
- Transaction value
- $19,391
- Shares
- -375
- Change %
- -0.81%
- Price
- $51.71
- Shares after
- 45,792
- Date
- 27 Feb 2026
- Ownership
- Direct
- Footnotes
- F2
MRNA
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +9,901
- Change %
- +22%
- Price
- Shares after
- 55,693
- Date
- 27 Feb 2026
- Ownership
- Direct
- Footnotes
- F1
MRNA
transaction
Common Stock
Tax liability
- Transaction value
- $247,587
- Shares
- -4,788
- Change %
- -8.6%
- Price
- $51.71
- Shares after
- 50,905
- Date
- 27 Feb 2026
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MRNA
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -329
- Change %
- -20%
- Price
- $0.000000
- Shares after
- 1,315
- Date
- 27 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 329
- Exercise price
- Footnotes
- F1, F3
MRNA
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -774
- Change %
- -11%
- Price
- $0.000000
- Shares after
- 6,189
- Date
- 27 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 774
- Exercise price
- Footnotes
- F1, F4
MRNA
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -9,901
- Change %
- -25%
- Price
- $0.000000
- Shares after
- 29,705
- Date
- 27 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,901
- Exercise price
- Footnotes
- F1, F5
MRNA
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +37,639
- Change %
- Price
- $0.000000
- Shares after
- 37,639
- Date
- 01 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 37,639
- Exercise price
- $53.57
- Footnotes
- F6
MRNA
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +49,569
- Change %
- Price
- $0.000000
- Shares after
- 49,569
- Date
- 01 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 49,569
- Exercise price
- Footnotes
- F1, F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 7 footnotes
Footnote F1
Restricted stock units convert into common stock on a one-for-one basis.
Footnote F2
Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units.
Footnote F3
25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
Footnote F4
25% of the shares subject to this restricted stock unit award vested on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
Footnote F5
25% of the shares subject to this restricted stock unit award vested on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
Footnote F6
25% of this option will vest and become exercisable on March 1, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
Footnote F7
25% of the shares subject to this restricted stock unit award will vest on March 1, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter.